[Translation] A single-center, double-blind, placebo-controlled, dose-escalating Phase Ia clinical study to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic characteristics of EA5 after a single dose in healthy adult subjects
一、评价EA5在中国健康成年受试者中单次剂量递增静脉注射的安全性和耐受性。
二、评价EA5在中国健康成年受试者中单次剂量递增静脉注射的药代动力学(PK)特征。
三、评价EA5在中国健康成年受试者中单次剂量递增静脉注射的药效动力学(PD)特征。
? 评价EA5在中国健康成年受试者中单次剂量递增静脉注射的免疫原性。
[Translation] 1. Evaluate the safety and tolerability of EA5 after single ascending dose intravenous injection in healthy Chinese adult subjects.
2. Evaluate the pharmacokinetic (PK) characteristics of EA5 after single ascending dose intravenous injection in healthy Chinese adult subjects.
3. Evaluate the pharmacodynamic (PD) characteristics of EA5 after single ascending dose intravenous injection in healthy Chinese adult subjects.
? Evaluate the immunogenicity of EA5 after single ascending dose intravenous injection in healthy Chinese adult subjects.